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The 5-HT
2A receptor is highly involved in aspects of cognition and executive function and seen to be affected in neurodegenerative
diseases like Alzheimer’s disease and related to the disease pathology. Even though Parkinson’s disease (PD) is primarily a motor
disorder, reports of impaired executive function are also steadily being associated with this disease. Not much is known about
the pathophysiology behind this. The aim of this study was thereby twofold: (1) to investigate 5-HT
2A receptor binding levels in
Parkinson’s brains and (2) to investigate whether PD associated pathology, alpha-synuclein (AS) overexpression, could be associated
with 5-HT
2A alterations. Binding density for the 5-HT2A-specific radioligand [
3H]-MDL 100.907 was measured in membrane
suspensions of frontal cortex tissue from PD patients. Protein levels of AS were further measured using western blotting. Results
showed higher AS levels accompanied by increased 5-HT
2A receptor binding in PD brains. In a separate study, we looked for
changes in 5-HT
2A receptors in the prefrontal cortex in 52-week-old transgenic mice overexpressing human AS. We performed
region-specific 5-HT
2A receptor binding measurements followed by gene expression analysis. The transgenic mice showed lower
5-HT
2A binding in the frontal association cortex that was not accompanied by changes in gene expression levels. This study is one
of the first to look at differences in serotonin receptor levels in PD and in relation to AS overexpression.
1. Introduction
Parkinson’s disease (PD) is clinically characterized by motor
symptoms consisting of bradykinesia, resting tremor, rigidity,
and postural instability. One of the leading hypotheses for PD
pathogenesis focuses on alterations in alpha-synuclein (AS)
expression, neuronal accumulation, and aggregation of AS—
including formation of Lewy bodies—as a main causative
factor in the pathological cascade [1]. Though PD principally
is classified as amovement disorder, it has nowbecome recog-
nised that PD features a complex burden of different motor
and nonmotor symptoms (NMS) [1, 2]. NMS covers a range
of symptoms including hyposmia, visual hallucinations, sleep
disturbances, a variety of dysautonomic symptoms, depres-
sion and other mood disorders, and impairment of cognition
and consequently affected executive function [3].
The key brain area involved in cognition and execu-
tive function is the prefrontal cortex (PFC). The serotonin
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Table 1: Overview of postmortem brain tissue samples used in binding assay analysis showing sample number, diagnosis/cause of death
(COD) (PD patients or controls dead of other nonneurological causes), age at time of death (age (death)), gender, and PMI (postmortem
interval). CP = cardiopulmonary and GI = gastrointestinal.
Parkinson’s disease (PD) frontal cortex samples Controls frontal cortex samples
Diagnosis/COD Age of death Gender PMI∗ Diagnosis/COD Age of death Gender PMI∗
PD 71 M 23,42 CP 59 M 61
PD 75 M 26,06 GI 81 F 35
PD 84 F 18,92 CP 58 M 43
PD 77 M 11,23 GI 74 F 24
PD 70 M 24,12 GI 70 F 72
PD 66 M 11,21 GI/cancer 69 M 23
PD 85 F 26,25
Mean 75,4 5 M/2 F 20,2 Mean 68,5 3 M/3 F 43
∗PMI = postmortem interval: time from death to tissue sample collection.
5-HT
2A receptor is highly expressed in PFC areas, playing an
important role in executive function [4] and in modulating
the cognitive control of our emotional responses during
decision-making [5], making them essential for inhibitory
response control, which recently has been shown to be
impaired in PD patients [6]. Alterations in cortical 5-HT
2A
receptor levels have been reported in Alzheimer’s disease
patients [7]. We have shown how this is associated with beta-
amyloid accumulation in transgenic mice models of beta-
amyloid overexpression [8]. Here we wanted to investigate
whether this could also be the case for PD.
The aim of this study was, on one side, to look for 5-HT
2A
receptor alterations in the frontal cortex of postmortem brain
tissue from PD patients and, secondly, to investigate by use
of transgenic mice whether overexpression of AS would lead
to alterations in frontal cortical 5-HT
2A receptors. Alterations
in serotonergic innervation have previously been described in
relation to PD [9], but information is lacking about the extent
to which serotonin receptors, and more specifically 5-HT
2A
receptors in PFC, are affected in this disease.
For the first approach, we used membrane suspensions
of human frontal cortex tissue of PD and control brains in
order to perform receptor binding studies with the 5-HT
2A-
specific radioligand, [3H]-MDL 100907, and furthermore
measured AS protein levels by western blotting. Second, we
used a transgenic mouse model overexpressing human AS to
examine region-specific 5-HT
2A receptor changes by autora-
diography analysis of [3H]-MDL 100.907 binding, followed
by gene expression analysis.
2. Materials and Methods
2.1. 5-HT2A Receptor Binding Assay in Human Frontal Cortex
Tissue. Postmortem frontal cortex brain tissue (BA9 region)
from PD patients and controls, deceased from nonneuro-
logical causes, was used for the binding assay. All brain
samples were fresh-frozen, stored at minus 80∘C until further
use. Brains were acquired from the Harvard Brain Tissue
Resource Center, USA, and the Brain Bank at Bispebjerg Uni-
versity Hospital (Copenhagen, Denmark) (BBH-2010-06, I-
suite number 00971). The initial total number of samples was
𝑛 = 8 for PD and 𝑛 = 7 for controls, but one sample from each
group was excluded from further analysis as they showed
significance in a Grubbs outlier test. The PD and control
samples included in the statistical analysis are listed in Table 1.
Brain tissue samples from PD patients were provided
by the Harvard Brain Tissue Resource Center, USA. The
mean age at death for the patients was 75.4 years and mean
postmortem index (PMI)—time from death to autopsy—was
20.2 hours. Brain tissue samples for the controls were pro-
vided by the Brain Bank of the Research Laboratory for
Stereology andNeuroscience, BispebjergUniversityHospital,
Denmark. The causes of death in the control group were
gastrointestinal (GI), cardiopulmonary (CP), and/or cancer
related, and mean age at death was 68.5 years and mean PMI
was 43.0 hours. There was no significant difference between
the PD and control group in terms of age of death (Student’s
𝑡-test, 𝑝 > 0.05) and gender distribution (chi-squared test,
𝑝 > 0.05), while there was a significant difference in PMI
(Student’s 𝑡-test, 𝑝 < 0.05).
For the brain membrane preparation, 450mg frontal cor-
tex tissue of each sample was homogenized in HEPES-buffer
(25mM HEPES, 120mM NaCl, 5mM KCl, 1.2mM CaCl
2
,
and 1.2mM MgSO
4
, pH = 7.5). The homogenate was spun
down for 5minutes, resuspended, and spun down again for 10
minutes at 4700 rpm and again resuspended in buffer in order
to obtain a 5%membrane suspension (MS).Three aliquots of
the MS were stored at minus 20∘C until further use. Three
independent but identical saturation binding assays were
performed on three different days for each sample. Brain
samples were blinded. For each assay, 100 𝜇L of the MS was
added to each well in a 24-well plate together with 100 𝜇L
[3H]-MDL 100.907 (at six different concentrations: 0.14; 0.28;
0.53; 1.07; 2.12; 4.63 nM) and HEPES-buffer until reaching a
total volume of 300 𝜇L. For the nonspecific binding (NSB)
10 𝜇MunlabelledMDL 100.907 was added to each of the con-
centrations.Three total binding (TB) andNSBmeasurements
were obtained for each concentration of [3H]-MDL 100.907.
Incubation time was 1 hour at room temperature.
Before filtration 1mL ice-cold HEPES-buffer was added
to each well. Membranes were filtered on printed Filtermat
B90–120mm from Wallac covered with polyethyleneimine
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(PEI) 0.05% using a Connectorate filtration machine fitted
with a 24-pin head (Connectorate AG,Dietikon, Switzerland).
The filters were washed in ice-cold HEPES-buffer for 30
seconds and left to dry on a heating plate at 98∘C. Once
dried, filters were covered with MeltiLex scintillation gel and
counted on the scintillation counter (6-channel micro beta
counter, Perkin Elmer). The three measurements for each
concentration point were averaged into one measurement
and specific binding (SB) was determined as the difference
between TB and NSB and plotted against ligand concentra-
tion in GraphPad. 𝐾
𝑑
and 𝐵max values for each sample were
calculated according to a nonfit linear analysis curve. Protein
concentration was determined from wet weight.
2.2. AS Protein Levels in Human Frontal Cortex Tissue Mea-
sured by Western Blotting. For the tissue lysate preparation,
50mg of tissue was dissected out from the 7 PD and 6
normal controls brains from equivalent area as above and
placed immediately in ice-cold Tissue Extraction Reagent II
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA)
containing protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO, USA). The tissue samples were homogenized
using the MagNA Lyser Instrument (2x 6000 rpm, 25 s)
and related MagNA Lyser Green Beads (Roche), in an
appropriate volume of tissue extraction reagent (10mL/g).
The homogenates were incubated on ice for 10 minutes and
centrifuged at 16 000×g for 20 minutes at 4∘C. The super-
natants were collected, separated into aliquots, and stored at
minus 80∘C until use. A portion of the supernatant was
reserved for protein determination using the Bradford
reagent (Sigma-Aldrich) and subsequent measurement of
absorbance was done at 595 nm using bovine serum albumin
as standard.
Next, samples were prepared for electrophoresis by
diluting each 20 𝜇g of protein lysate with a 4x NuPAGE
sample buffer containing 2mM of cross-linker dithiobis[suc-
cinimidylpropionate] (DSP) (Pierce, Thermo Fisher Scien-
tific, Waltham, MA, USA). DSP was dissolved in dimethyl
sulfoxide to a 50x stock concentration prior to addition to the
protein samples. Samples were incubated with cross-linker
for 30 minutes at 37∘C, followed by addition of 5% 𝛽-
mercaptoethanol (𝛽ME) and incubation at 70∘C for 10
minutes. The application of reducible amine-reactive cross-
linker DSP followed by reductive cleavage (5% 𝛽ME) prior
to sodium dodecyl sulfate polyacrylamide gel electrophoresis
and electroblotting improves significantly immunodetection
of alpha-synuclein monomers [10].
The samples were electrophoresed on NuPAGE 4–
12% Bis-Tris Gels with NuPAGE 2-(N-morpholino)etha-
nesulfonic acid-sodium dodecyl sulfate (Life Technologies)
running buffer and Novex Sharp Pre-Stained Protein Stan-
dard (Life Technologies). As standards, we used 10𝜇g of
human recombinant full-length alpha-synuclein (rPeptide)
treated and loaded on gels simultaneously with the tissue
lysates. After electrophoresis, gels were blotted ontoOdyssey
nitrocellulose membranes 0.22𝜇m (LI-COR Biosciences,
Cambridge, UK) using the semidry Bio-Rad apparatus (Bio-
Rad Laboratories, Hercules, CA, USA) for 60 minutes, using
a 200mA/membrane constant current in NuPAGE transfer
buffer (Life Technologies) containing 20% methanol. Post-
transfer membranes were treated with 0.4% paraformalde-
hyde in phosphate-buffered saline (PBS) for 30 minutes at
21∘C, rinsed withMilli-Q water, and then blocked in Odyssey
blocking buffer (PBS) (LI-COR) for 1 hour at 21∘C. Treatment
with low concentrations of paraformaldehyde prevents wash-
ing off alpha-synuclein from nitrocellulose membranes [11].
Blots were then incubated overnight at 4∘C with rabbit
monoclonal anti-alpha-synuclein antibody MJFR1 (Abcam
# ab138501, 1 : 5000) in Odyssey blocking buffer with 0.1%
Tween-20. All membranes were at the same time also incu-
bated with an anti-GAPDH antibody (clone FL-335) (# SC-
25778, 1 : 1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) as a loading control. Membranes were then washed 3x
15 minutes in PBS with 0.1% Tween-20 and incubated in
secondary antibody IRDye 800CW Goat anti-rabbit IgG (#
926-32211; LI-COR Biosciences) 1 : 15 000 and IRDye 680LT
Goat anti-mouse IgG
1
-specific (# 926-68050; LI-COR Bio-
sciences) 1 : 20 000 in PBS + 0.1% Tween + 0.01% sodium
dodecyl sulfate at 21∘C in the dark. Subsequently, the mem-
branes were washed 3x 15 minutes in PBS, rinsed in Milli-
Q water, air dried, and developed on LI-COR Bioscience
Odyssey 9120 Infrared Imaging System.
Scanned western blots were analyzed with Image Studio
Lite software v.5.2 (LI-CORBiosciences).The infrared signals
after background subtraction were normalized to the loading
control signal.
2.3. Transgenic Animals, h-SNCA Mice, Overexpressing
Human Alpha-Synuclein. Mice used in the study were male,
52-week-old, transgenic (tg) F28SNCA mice on a C57BL/6
background (𝑛 = 10) overexpressing wild-type human SNCA
(anAS coding gene) under the control ofmouse AS promoter
[12, 13] and C57BL/6 wild-type (wt) mice (𝑛 = 10) (Taconic,
H. Lundbeck A/S, Denmark). All animal experiments were
approved by the Danish Veterinary and Food Administration
(DVFA) and were conducted in accordance with European
standards on animal welfare.
2.4. Ligands. The 5-HT
2A receptor antagonist, [
3H]-MDL
100.907, [R-(+)-𝛼-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophe-
nyl)-ethyl]-4-piperidine-methanol], was synthesized and
radiolabelled by NOVANDI Chemistry AB, Sweden. The
specific activity of [3H]-MDL 100.907 was determined to be
75.676Ci/mmol (2.8 Tbq/mmol). Radiochemical purity was
greater than 97%.
2.5. 5-HT2A Receptor Autoradiography. Mice were decapi-
tated and brains rapidly removed and frozen on powdered
dry ice and kept at minus 80∘C until sectioning. Prefrontal
cortex regions were cut into 15 𝜇mcoronal sections on a cryo-
stat, thaw-mounted onto Superfrost Plus slides, and stored
at minus 20∘C until further processing.
Autoradiography was performed using 1 nM [3H]-MDL
100.907 for 5-HT
2A receptor TB, with addition of 10 𝜇M
ketanserin to determine NSB. Briefly, sections were thawed at
room temperature for a minimum of 30 minutes prior to the
experiment. For preincubation, sections were submerged in
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5∘C tris-buffer (50mM tris-HCl buffer, pH = 7.4, with 0.01%
ascorbic acid) for 15 minutes—with or without ketanserin.
Sections were incubated for 120 minutes at 5∘C in tris-buffer
with the ligand, with or without ketanserin. Concentrations
of radioligand were determined using a scintillation counter.
After incubation, slides were dipped in ice-cold tris-buffer for
5 seconds. Slices were then washed again 2x 15minutes in ice-
cold tris-buffer and dipped in ice-cold dH
2
O for 20 seconds.
Sections were left to dry under a fume hood overnight.
After drying, sections were exposed for 5 weeks to a BAS
IP-TR2040 Fuji Imaging Plate (Science Imaging, Sweden)
together with [3H] specificmicroscales at 4∘C. Imaging plates
were scanned on the BAS-2500 Phosphor Image Scanner:
FLA-9000, Starion. ImageJ was used for densitometric anal-
ysis of signal intensity. Concentrations were expressed as
nCi/mg. Quantification was performed blindly in separate
regions of interest (ROIs) according to Paxinos and Franklin’s
atlas of the mouse brain [14].
2.6. RT-qPCR Quantification of 5-HT2A-R Expression. RNA
was extracted from fresh frontal cortex sections that were
scraped off from parallel slides to the ones allocated for
the receptor autoradiography analysis. For each animal, a
total of 12 coronal frontal sections of 15 𝜇m thickness were
pooled together. Total RNA was purified using the Pure-
Link RNA Mini Kit (Ambion) following the manufacturer’s
instructions. All RNA samples were treated once with DNase
using TURBO DNA-free Kit (Ambion) according to the
manufacturer’s instructions. RNA samples were suspended
in RNase-free water and were quantified using Agilent 2100
Bioanalyzer (Agilent Technologies). Only samples with RIN
≥ 6 were included in the analysis. RNA samples were stored
at minus 80∘C until further use.
A two-step real-time PCR was subsequently performed:
RNA samples matched on concentration were reverse tran-
scribed into cDNA with qScript cDNA SuperMix Kit
(Quanta BioSciences) according to manufacturer’s instruc-
tions. SuperMix reaction mixture consisted of 5x reaction
buffer containing optimized concentrations ofMgCl
2
, dNTPs
(dATP, dCTP, dGTP, and dTTP), recombinant RNase inhi-
bitor protein, qScript reverse transcriptase, random primers,
oligo(dT) primers, and stabilizers. cDNA synthesis step was
performed following incubation times of 5 minutes at 25∘C,
30 minutes at 42∘C, 5 minutes at 85∘C, and 5 minutes at 25∘C.
Thereafter cDNA product was diluted 5-fold in nuclease-free
water and kept at minus 20∘C until further use.
To check RNA samples for contamination with nuclear
DNA a negative control PCR was done on all samples prior
to cDNA synthesis omitting the reverse transcription step.
Real-time PCR reactions were performed using Per-
feCTa SYBR Green FastMix (2x) Kit (Quanta BioSciences)
with forward and reverse primers specific for the 5-HT
2A
receptor (mouse), Rpl13a (mouse reference gene), and
GAPDH (mouse reference gene) (TAGCopenhagen). Primer
sequences were as follows: 5-HT
2A: F = 5
󸀠-GCA GTC CAT
CAG CAA TGA GC-3󸀠 and R = 5󸀠-GCA GTG GCT TTC
TGT TCT CC-3󸀠; Rpl13a: F = 5󸀠-GGA GGG GCA GGT TCT
GGT AT-3󸀠 and R = 5󸀠-TGT TGA TGC CTT CAC AGC
GT-3󸀠; GAPDH: F = 5󸀠-CAT CAA GAA GGT GGT GAA
GCA-3󸀠 andR= 5󸀠-CTGTTGAAGTCACAGGAGACA-3󸀠.
qPCR was performed with 30 seconds for initial activation at
95∘C, then 40 cycles of 5 seconds at 95∘C for denaturation, 15
seconds at 60∘C for annealing (END read), and 10 seconds
at 72∘C for elongation. To verify product a melting curve
analysis between 55 and 95∘C was performed after each run.
Relative quantification (target/reference) was made using the
ΔCt method [15].
2.7. Statistical Analyses. All statistical analyses were per-
formed in GraphPad Prism 6. Significance level was set at a
𝑝 value ≤ 0.05. All values are presented as mean ± standard
error of the mean (SEM). Student’s 𝑡-test was used for com-
paring mRNA levels for the receptors analyzed, AS protein
levels, and 𝐾
𝑑
and 𝐵max values between the PD and control
brain samples. Multiple 𝑡-tests were used for comparing
receptor binding levels in h-SNCA tg and wt mice for the
different ROIs.
3. Results
3.1. Higher 5-HT2A Receptor Binding in Postmortem Prefrontal
Cortex of PD Patients. The binding assay, performed on
human brain tissue from the frontal cortex, showed a sig-
nificant difference in 𝐵max of the 5-HT2A receptor between
PD (𝑛 = 7) and control (𝑛 = 6) brain samples, with higher
maximum binding level in the PD group (PD: 5.7 ± 1.0;
controls: 3.2 ± 0.35; Student’s test 𝑝 < 0.05) (Figure 1(a)).
There was no significant difference between the PD and
control group when comparing 𝐾
𝑑
(affinity) (PD: 0.5 ± 0.07;
controls 0.3 ± 0.05; 𝑝 > 0.05). Mean PMI (postmortem
interval) was different between the two groups (PD and
controls). We controlled for a potential effect of the PMI on
binding results, and no correlation between 𝐵max and PMI
(𝑟 = −0.52, 𝑝 > 0.05) or between 𝐾
𝑑
and PMI (𝑟 = −0.32,
𝑝 > 0.05) was found.
3.2. IncreasedAS Protein Levels in the Prefrontal Cortex Region
of PD Brains. Detergent soluble monomeric AS protein
levels, as measured by electrophoresis and immunoblotting,
were increased in the PD brains compared to controls (PD:
2.56 ± 0.27; controls: 1.56 ± 0.3; Student’s test 𝑝 < 0.05)
(Figure 1(b)). No correlation was observed between AS
protein and 5-HT
2A receptor binding levels in the PD brains
(Spearman 𝑟 = −0.48; 𝑝 > 0.05).
3.3. Region-Specific Differences in 5-HT2A and 5-HT1A Recep-
tor Binding in ASOverexpressingMice. The regions of interest
(ROIs) included FrA (frontal association cortex), PrL + Cg1/2
(prelimbic cortex and cingulate cortex), MO (medial orbital
cortex), DLO (dorsolateral orbital cortex), M1 and M2 (pri-
mary and secondarymotor cortex), andAI (agranular insular
cortex). Results from the [3H]-MDL 100.907 autoradiog-
raphy binding analysis showed significantly lower 5-HT
2A
receptor binding in FrA of h-SNCA mice (h-SNCA: 102.2 ±
6.5 fmol/mg; wt 126.7 ± 8.0 fmol/mg; 𝑝 < 0.05). There were
no significant differences in 5-HT
2A receptor binding in the
other ROI measured (Figure 2(a)).
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Figure 1: Receptor binding analysis and alpha-synuclein levels in postmortem prefrontal cortex of Parkinson’s disease (PD) patients. (a)
Binding assays with [3H] MDL100.907 comparing membrane suspensions from postmortem prefrontal cortex of Parkinson’s disease (PD)
patients and controls show higher maximum binding levels (𝐵max) of the 5-HT2A receptor in the PD group. (b) Western blot showing higher
levels of alpha-synuclein proteins in the PD brains included in the binding assay. Control = normal controls; PD=Parkinson’s disease patients.
Significant ∗𝑝 < 0.05. Student’s 𝑡-test with mean ± SEM.
3.4. No Difference in 5-HT2A Receptor Gene Expression Levels.
Results from RT-qPCR show no difference in 5-HT
2A (h-
SNCA: 0.01 ± 0.003; wt 0.007 ± 0.001; 𝑝 > 0.05) receptor
gene expression in the frontal cortex of h-SNCA mice when
compared to wt mice (Figure 2(b)).
4. Discussion
In this study we looked at alterations in 5-HT
2A receptor
binding levels in the frontal cortex from PD patients, and
using a tg h-SNCAmouse model, we furthermore looked for
whether AS overexpression could be associated with changes
in 5-HT
2A receptor binding and gene expression. In vitro
receptor binding studies on postmortembrain tissue fromPD
patientswith increasedAS levels indeed revealed significantly
higher 5-HT
2A receptor binding levels, as indicated by higher
maximum binding (𝐵max) in the PD brains. Results obtained
using the well validated human AS overexpressing mouse
model [12, 13] showed lower 5-HT
2A receptor binding levels
in FrA cortex in the h-SNCA transgenic mice. Differences
in 5-HT
2A receptor binding levels were not accompanied by
decreased gene expression.
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Figure 2: 5-HT
2A receptor mouse prefrontal cortex autoradiography binding analysis and gene expression levels. (a) Results from [
3H]MDL
100.907 (5-HT
2A) binding. FrA [
3H] MDL 100.907 binding is significantly lower in alpha-synuclein overexpressing (SNCA) mice compared
to wt mice. Bars: grey: wild-type mice (𝑛 = 9); black: SNCA mice (𝑛 = 10). ∗𝑝 < 0.05. Multiple 𝑡-test. Data illustrated with mean ± SEM.
(b) Results from RT-qPCR show CT ratios (calculated using CT-ratio (receptor/reference) = 2(CT (reference) − CT (receptor))) comparing alpha-
synuclein overexpressing (SNCA) and wt mice. Reference genes are Rpl13a and GAPDH. No difference in receptor gene expression was
found. Bars show mean ± SEM.
To our knowledge this is one of the first studies directly
looking at 5-HT
2A receptor binding levels in postmortem
tissue samples from the frontal cortex of PD brains in relation
to Parkinson’s disease associated pathology of AS overex-
pression. Previously, at least two studies had addressed the
question of 5-HT
2A receptor alterations in the frontal cortex
of PD brains. A study from 1998 examined postsynaptic
5-HT
2A receptors in the neocortex of eight PDpatients [16]. It
too found an increase in 5-HT
2A receptor binding in PFC of
postmortem PD tissue, using ligands other than those in this
study (8-OH-DPAT and ketanserin). More recently, a Single-
Positron-Emission-Tomography (SPECT) study, using the
[123I]-5-I-R91150 ligand, reported lower 5-HT
2A receptor
binding in the anterior striatum and premotor cortex and
increased 5-HT
2A receptor binding in the occipital cor-
tex of untreated PD patients [17]. However, no significant
differences in 5-HT
2A receptor binding were detected in
the prefrontal and parietal cortices. This discrepancy with
our findings could be explained by the fact that patients
included in the latter study were in early stages of the disease
and therefore not directly comparable to our patient group
consisting of end stage PD patients. According to Braak
staging of PD, the raphe nuclei, the origin of the serotonergic
projection to the substantia nigra, striatum, globus pallidus,
subthalamic nucleus, thalamus, and neocortex with connec-
tions to cortical regions including frontal cortex and PFC
areas—core structures of the cortico-basal ganglia-thalamo-
cortical loop compromised in PD [9]—become increasingly
affected in stage 2 and are completely affected in stage 3
[18, 19]—hence, the serotonergic system is mostly affected
at later stages of the disease. Another explanation could be
that, contrary to the study byMelse et al. [17], which included
unmedicated patients, we cannot exclude an effect of the
medical treatment on the receptor upregulation observed in
our PD patients.
In addition to higher binding levels of 5-HT
2A receptor
in the frontal cortex of PD brains, our study found higher
concentration of AS in PD compared to controls, which
corresponds well with the view that accumulation of AS plays
a significant role in PD pathology. Overall, it is important
to take into consideration that both in the study by Melse et
al. [17] and Chen et al. [16] and in our study relatively small
sample sizes were used with risk of inconclusive results. With
that in mind, we can nevertheless agree that the joint results
point towards disease related changes in 5-HT
2A receptor
levels that could be associated with some of the cognitive and
executive dysfunction seen in PD.More studies are needed to
pursue this idea further.
In the second part of our study, our aim was to inves-
tigate whether alterations in 5-HT
2A receptor binding and
expression could be associated with AS overexpression. Here
decreased binding levels of 5-HT
2A receptor were found in
FrA in AS overexpressingmice.This region is part of the PFC
area, and even though its exact function is still unknown,
FrA is most likely involved in some of the cognitive processes
related to executive function.The FrA has been proposed in a
human study to be important for go/no-go task performance
[20]. The go/no-go task measures attention and response
inhibition control [21], and interestingly these are functions
impaired in newly diagnosed drug na¨ıve PD patients [6].
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The differences in receptor binding levels observed in the
AS overexpressingmice were not accompanied by differences
in gene expression. The lower receptor binding in the h-
SNCAmice could therefore be due to regulatory effects at the
posttranslational level.
Why the changes in 5-HT
2A receptor binding levels
display opposite directions in the PD brains and in the
transgenic animal model of AS overexpression is puzzling.
In the mouse model we isolate a specific segment of the
underlying pathology behind PD—that is AS overexpression.
In the human tissue all aspects of PD pathology along with
AS overexpression, that is, dopaminergic degeneration, play
in, thus adding to the complexity of mechanisms that may
influence the 5-HT
2A receptor. Striatal degeneration also
results in decreased 5-HT
2A binding in PFC, as seen in a
6-hydroxydopamine-induced parkinsonian rat model [22].
Changes in 5-HT
2A receptor levels are probably the result
of a more multifaceted pathology behind PD, not directly
related to AS overexpression. We cannot exclude that the
receptor upregulation observed in the PD brains can also be
due to compensatory drug effects administered to this group
of patients, that is, antidepressants or antipsychotics; as we do
not have access to this information from the patient material
used for this study we cannot determine this.
In summary, in PD brains we find higher levels of 5-HT
2A
receptor binding together with higher levels of AS. An asso-
ciation is not supported by transgenic mouse model results,
thus pointing towards amore complex andmultidimensional
explanation for 5-HT
2A changes found in PD. Nevertheless,
the most important finding from the present study is that the
5-HT
2A receptor seems to be dysregulated in PD. Progress
in the area of 5-HT
2A targeting treatment is already being
manifested in management of PD psychosis for example
[23]. Addressing this receptor in future studies is relevant
for understanding and treating some of the cognitive and
executive dysfunction seen in PD.
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